New Posts New Posts RSS Feed - OPEN ACCESS links, articles, TNBC
  FAQ FAQ  Forum Search   Events   Register Register  Login Login

OPEN ACCESS links, articles, TNBC

 Post Reply Post Reply Page  <1 8910
Author
 Rating: Topic Rating: 2 Votes, Average 3.00  Topic Search Topic Search  Topic Options Topic Options
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 736
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Aug 27 2013 at 4:55pm
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 736
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Aug 29 2013 at 9:59pm
Problems with public reporting of clinical trials:
http://jco.ascopubs.org/content/31/24/2981.long

Quotes from article:

"They found that almost one half of trials had no publically available results at 3 years after completion."

"The consequences of nonreporting study results—in particular, those from clinical trials with statistically nonsignificant findings or where significant toxicities are identified which are more likely to remain unpublished7—have far reaching effects."

And importantly:
"Finally, study investigators must remember their commitment to research participant volunteers as well as future patients to see complete pictures of oncologic drugs."
12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
Tracy View Drop Down
Groupie
Groupie
Avatar

Joined: Jul 20 2008
Location: United States
Status: Offline
Points: 52
Post Options Post Options   Thanks (0) Thanks(0)   Quote Tracy Quote  Post ReplyReply Direct Link To This Post Posted: Nov 03 2013 at 6:49pm
Hi Martha, where are you being treated? After 5.5 years I had a new primary that grew lightning fast. I was worked up in San Diego and MDA. My tumor this time was also the aggressive sarcamatoid. I think I spelled it right. That thing came back 3 days after my first chemo. In the same place as the lumpectomy. Shocked all. So I had an immediate left breast masectomy and nodes. About 3 week went by between the last physical exam and when chemo started. I also had a mediastinal node biopsied as 3 were enlarged. The one the biopsied was negative. I'm on Ixempra and Xeloda chemo. I'm very very interested in this trial or whatever you call it. I may need more. Appreciate knowing where you go. Your doc name. Thank you. Best of all luck.
Tracy

San Diego

DX 12/20/07, Stage 2, TNBC, Grade 3/2.5 cm

Chemo start 2/14/08; rads ended 9/08; A/C - Taxol; Neg. Sentinol Node; lumpectomy; past 5 years!
Back to Top
Lee21 View Drop Down
Senior Member
Senior Member
Avatar

Joined: Dec 22 2011
Location: Michigan
Status: Offline
Points: 736
Post Options Post Options   Thanks (0) Thanks(0)   Quote Lee21 Quote  Post ReplyReply Direct Link To This Post Posted: Dec 01 2013 at 9:31pm

Reputable resources on complementary medicine

• American Cancer Society. Guidelines for Using Complementary and Alternative Methods (http://www.cancer.org/Treatment/TreatmentsandSideEffects/ComplementaryandAlternativeMedicine/guidelines-for-using-complementary-and-alternative-methods)

• Medline Plus. Herbs and Supplements (http://www.nlm.nih.gov/medlineplus/druginfo/herb_All.html)

• Memorial Sloan–Kettering Cancer Center. About Herbs, Botanicals & Other Products (http://www.mskcc.org/aboutherbs)

• Memorial Sloan–Kettering Cancer Center. Integrative Medicine (http://www.MSKCC.org/IntegrativeMedicine)

• National Cancer Institute. Topics in Complementary and Alternative Therapies (PDQ®; http://www.cancer.gov/cancertopics/pdq/cam/topics-in-cam/healthprofessional)

• National Center for Complementary and Alternative Medicine (NCCAM). Cancer and Complementary Health Practices (http://nccam.nih.gov/health/cancer/camcancer.htm)

• NCCAM. Time to Talk: Ask Your Patients About Their Use of Complementary Health Practices (http://nccam.nih.gov/timetotalk/forphysicians.htm)

• NIH Office of Dietary Supplements. Dietary Supplement Fact Sheets (http://ods.od.nih.gov)

• Society for Integrative Oncology (http://www.integrativeonc.org)

• US Pharmacopeial Convention. USP Dietary Supplement Standards (http://www.usp.org/dietary-supplements/overview)

12/9/11 @59,IDC,grade3, TNBC,3cm(MRI),SLNB0,stage IIA, BRCA1 variant
1/30/12 DD AC-T, 6/7/12 Lumpectomy, ypT1b(0.8 cm), 7/9/12 Rads x 30
11/9/12, clinical trial cisplatin/rucaparib, cisplatin-only arm
Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12920
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: May 13 2016 at 7:49am
DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
123Donna View Drop Down
Senior Member
Senior Member
Avatar

Joined: Aug 24 2009
Location: St. Louis, MO
Status: Offline
Points: 12920
Post Options Post Options   Thanks (0) Thanks(0)   Quote 123Donna Quote  Post ReplyReply Direct Link To This Post Posted: Sep 25 2018 at 8:02am

Advances in the systemic treatment of triple-negative breast cancer


Triple-negative breast cancer constitutes a heterogeneous group of malignancies that are often aggressive and associated with a poor prognosis. Molecular characterization, while not a standard of care, can further subtype triple-negative breast cancer and provide insight into prognostication and behaviour. Optimal chemotherapy regimens have yet to be established; however, there have been advances in the systemic treatment of triple-negative breast cancer in the neoadjuvant, adjuvant, and metastatic settings. In this review, we discuss evidence for the potential benefit of neoadjuvant platinum-based chemotherapy, adjuvant combination chemotherapy with weekly paclitaxel, and BRCA mutation–directed therapy in the metastatic setting. The role for adjuvant capecitabine in patients who do not achieve a pathologic complete response with neoadjuvant chemotherapy is reviewed. Future directions and data concerning novel targeted agents are reviewed, including the most recent data on parp [poly (adp-ribose) polymerase] inhibitors, antiandrogen agents, and immunotherapy.

To read the entire article:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001760/

DX IDC TNBC 6/09 age 49, Stage 1,Grade 3, 1.5cm,0/5Nodes,KI-67 48%,BRCA-,6/09bi-mx, recon, T/C X4(9/09)
11/10 Recur IM node, Gem,Carb,Iniparib 12/10,MRI NED 2/11,IMRT Radsx40,CT NED11/13,MRI NED3/15

Back to Top
 Post Reply Post Reply Page  <1 8910
  Share Topic   

Forum Jump Forum Permissions View Drop Down

Forum Software by Web Wiz Forums® version 11.05
Copyright ©2001-2016 Web Wiz Ltd.